Przeklasa-Muszyńska Anna, Kocot-Kępska Magdalena, Dobrogowski Jan, Wiatr Maciej, Mika Joanna
Department of Pain Research and Treatment, Chair of Anesthesiology and Intensive Therapy, Medical College of Jagiellonian University, Kraków, Poland.
Chair and Department of Otolaryngology, Medical College of Jagiellonian University, Kraków, Poland.
Pharmacol Rep. 2016 Oct;68(5):1069-75. doi: 10.1016/j.pharep.2016.06.010. Epub 2016 Aug 20.
Neuropathic pain, is caused by damage or disease affecting the somatosensory nervous system, leads to deterioration of the quality of life of patients. Most commonly, this deterioration is due to the inefficacy of treatment or to the adverse effects of systemic treatment. Pharmacotherapy of neuropathic pain involves the use of antiepileptic agents, antidepressants, and opioids that may lead to numerous adverse effects, particularly in elderly patients. Intravenous infusions of lidocaine may improve the efficacy of the analgesic treatment of neuropathic pain patients while not causing any significant adverse effects.
In our study, we carried out a retrospective analysis of 85 patients with various neuropathic pain syndromes. In this group, 81 patients received 3-25 intravenous infusions of lidocaine (5mg/kg of body weight over 30min). In the remaining 4 patients, the treatment was discontinued after the first infusion due to the lack of efficacy.
The analgesic effect of intravenous lidocaine was better when the intensity of pain experienced before the infusion was high. In addition, better effects were observed in elderly patients. No need to interrupt the infusion occurred in any of the patients. No serious adverse effects were observed either. Transient dizziness, not requiring additional treatment, occurred in 5 patients after the infusion.
The best therapeutic effects of lidocaine infusion was observed in pain symptoms characterized by the highest intensity of baseline pain. Intravenous lidocaine administered at the dose of 5mg/kg of body weight over 30min is effective, safe and caused no significant adverse effects.
神经性疼痛是由影响躯体感觉神经系统的损伤或疾病引起的,会导致患者生活质量下降。最常见的是,这种下降是由于治疗无效或全身治疗的不良反应所致。神经性疼痛的药物治疗包括使用抗癫痫药、抗抑郁药和阿片类药物,这些药物可能会导致许多不良反应,尤其是在老年患者中。静脉输注利多卡因可以提高神经性疼痛患者镇痛治疗的效果,同时不会引起任何明显的不良反应。
在我们的研究中,我们对85例患有各种神经性疼痛综合征的患者进行了回顾性分析。在这组患者中,81例接受了3至25次利多卡因静脉输注(30分钟内每公斤体重5毫克)。其余4例患者在首次输注后因无效而停止治疗。
当输注前疼痛强度较高时,静脉注射利多卡因的镇痛效果更好。此外,在老年患者中观察到更好的效果。所有患者均无需中断输注。也未观察到严重不良反应。5例患者在输注后出现短暂头晕,无需额外治疗。
在基线疼痛强度最高的疼痛症状中观察到利多卡因输注的最佳治疗效果。以每公斤体重5毫克的剂量在30分钟内静脉注射利多卡因是有效、安全的,且不会引起明显的不良反应。